Bristol-Myers Squibb

Featured Drug Company Program


Bristol-Myers Squibb Access Support

800-861-0048
www.bmsaccesssupport.com

Bristol-Myers Squibb Patient Assistance Foundation

800-736-0003
www.bmspaf.org

Through its Access Support program, Bristol-Myers Squibb (BMS) offers a variety of oncology support options for patients receiving outpatient treatment in the United States and Puerto Rico, and, in certain circumstances, the Virgin Islands.

The BMS Access Support program offers a variety of oncology support options for eligible patients who are unable to afford their medications. These may include reviewing patient insurance coverage for BMS medications, the BMS Oncology Co-Pay Program, navigating prior authorization, and claims appeals if coverage is denied, or referring the patient to other financial assistance options for the uninsured or underinsured.

The Table lists the oncology and oncology supportive drugs that are included in the BMS Access Support program. Oral drugs may be shipped to the provider or patient.

Table BMS Oncology Drugs
Drug Indications Patient support programs Contact information
Droxia
(hydroxyurea)
Melanoma; chronic myeloid leukemia; ovarian cancer; squamous-cell head and neck cancer (primary) Good Days www.mygooddays.org
877-968-7233
Empliciti
(elotuzumab)
Multiple myeloma, in combination with lenalidomide and dexamethasone BMS Access Support www.bmsaccesssupport.bmscustomerconnect.com/oncology/products/empliciti
BMS Patient Assistance Foundation http://www.bmspaf.org
Etopophos
(etoposide phosphate)
Refractory testicular tumors; small-cell lung cancer    
Ixempra
(ixabepilone)
Metastatic or locally advanced breast cancer R-Pharm US Access and Support http://ixempra.com/#support
Lysodren
(mitotane)
Adrenal cortical carcinoma of functional and nonfunctional types    
Opdivo
(nivolumab)
Classical Hodgkin lymphoma that relapsed or progressed after autologous HSCT; newly diagnosed advanced melanoma with BRAF mutation; unresectable or metastatic melanoma with BRAF V600 wild-type; recurrent or metastatic squamous-cell head and neck cancer; metastatic non–small-cell lung cancer; advanced renal-cell carcinoma BMS Access Support www.bmsaccesssupport.bmscustomerconnect.com/oncology/products/opdivo
BMS Patient Assistance Foundation http://www.bmspaf.org
Opdivo (nivolumab) + Yervoy (ipilimumab) Unresectable or metastatic melanoma BMS Access Support www.bmsaccesssupport.bmscustomerconnect.com/opdivo-and-yervoy-regimen
Sprycel
(dasatinib)
Ph+ acute lymphoblastic leukemia; newly diagnosed Ph+ chronic myeloid leukemia; chronic, accelerated, or myeloid or lymphoid blast phase Ph+ chronic myeloid leukemia resistant or intolerant to previous therapyAdrenal cortical carcinoma of functional and nonfunctional types BMS Access Support www.bmsaccesssupport.bmscustomerconnect.com/oncology/products/sprycel
BMS Patient Assistance Foundation http://www.bmspaf.org
Sprycel Assist www.sprycel.com/sprycel-assist
Sprycel One Card
Yervoy
(ipilimumab)
Unresectable or metastatic melanoma BMS Access Support www.bmsaccesssupport.bmscustomerconnect.com/oncology/products/yervoy
BMS Patient Assistance Foundation http://www.bmspaf.org
HSCT indicates hematopoietic stem-cell transplantation; Ph+, Philadelphia chromosome–positive.

The BMS Access Support program can refer you to independent charitable foundations that may be able to provide financial support, including the Bristol-Myers Squibb Patient Assistance Foundation, a charitable organization that provides medicine, free of charge, to eligible, uninsured patients who have an established financial hardship.

The BMS Patient Assistance Foundation accepts the Access Support application. For more information, you can visit www.bmspaf.org.

Eligibility

BMS Oncology Co-Pay Assistance Program

This program is designed for commercially insured patients who need financial assistance with out-of-pocket deductibles, copays, or coinsurance, as indicated in the Explanation of Benefits form.

Patients whose infusions are covered by a federal healthcare program, such as Medicare, Medicaid, Medigap, CHAMPUS, Department of Defense, TRICARE, or Veterans Affairs programs, are not eligible for this program. Eligible patients pay the first $25 of their copay per infusion; BMS will cover the remainder of their copay, up to $25,000 per 12-month enrollment period per medication.

The program covers select BMS oncology drugs, including Empliciti (elotuzumab), Opdivo (nivolumab), and Yervoy (ipilimumab).

BMS Patient Assistance Foundation

Eligible patients may qualify to receive medications free of charge for up to 1 year. To be eligible, patients:

  • Must be receiving outpatient treatment in the United States, Puerto Rico, or the US Virgin Islands by a US-licensed healthcare provider
  • Must meet the income limits for the requested medication and other insurance criteria; the annual income must be less than approximately 300% of the federal poverty level
  • May also be eligible if they are uninsured, have been denied coverage for the requested medication, or are enrolled in a Medicare Part D plan that covers the medication and have spent at least 3% of their annual household income on out-of-pocket costs for prescription medications this year.
For more information on this program, visit www.bmspaf.org, or call 800-736-0003.

Application & Enrollment

BMS Oncology Co-Pay Program

To enroll in the BMS Oncology Co-Pay Program, the enrollment form must be completed either online or faxed to 888-776-2370. Enrollment forms are available at www.bmsaccesssupport.com. BMS Access Support program will determine the patient’s eligibility, including verification of insurance coverage and benefits amount.

An explanation of benefits must be submitted within 180 days of receiving each dose. For more information on Sprycel Assist or the Sprycel One Card, visit www.sprycel.com or call 855-777-9235.

BMS Patient Assistance Foundation

An application to be filled out by the patient and healthcare provider is required to enroll in BMS Patient Assistance Foundation. Proof of income should be submitted with the application, and returned to the foundation by mail or fax to 800-736-1611.

The enrollment form is available at www.bmspaf.org. Enrollment is valid for 1 year; re-enrollment every year is required to continue in the program. For more information on this program, call 800-736-0003.

Receiving BMS Medications

Approved patients may have medications shipped directly to the patient’s home or to the healthcare provider’s office, depending on the type of medication and route of administration (oral or injection).

Opdivo is available through specialty pharmacies and may be purchased by physician offices, hospitals, and infusion centers via specialty distributors listed at www.bmsaccesssupport.bmscustomerconnect.com/oncology/products/opdivo.

For Sprycel, Sprycel Assist can provide information, support, and resources at all steps in the patient’s treatment. For more information on Sprycel Assist or the Sprycel One Card, visit www.sprycel.com or call 855-777-9235.

Yervoy may be purchased by physician offices, hospitals, and infusion centers via specialty distributors listed at www.bmsaccesssupport.bmscustomerconnect.com/oncology/products/yervoy#freqasked.